Gensight Biologics (XPAR:SIGHT) 3-Year Revenue Growth Rate : -40.80% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics 3-Year Revenue Growth Rate?

Gensight Biologics's Revenue per Share for the six months ended in Dec. 2023 was €-0.01.

During the past 12 months, Gensight Biologics's average Revenue per Share Growth Rate was -53.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -40.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of Gensight Biologics was 30.80% per year. The lowest was -40.80% per year. And the median was -5.00% per year.

Competitive Comparison of Gensight Biologics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Gensight Biologics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gensight Biologics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's 3-Year Revenue Growth Rate falls into.

Gensight Biologics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Gensight Biologics (XPAR:SIGHT) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Gensight Biologics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Gensight Biologics (XPAR:SIGHT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

GSGTF:USA G49N:Germany

Address

74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012

Website

https://www.gensight-biologics.com

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines